Paris-based Generare Raises €20 Million to Unlock Nature's Molecular Secrets for Drug Development

In a significant stride for biotech innovation, Paris-based startup Generare has secured €20 million in Series A funding. The company, known for its groundbreaking approach to drug discovery by decoding microbial genomes, aims to revolutionize the pharmaceutical industry by expanding its compound library and scaling its discovery platform.

Unlocking Nature’s Hidden Chemistry

Generare is pioneering a new frontier in drug discovery by tapping into the vast, uncharted chemical landscapes hidden within microbial genomes. Founded in 2023 by Dr. Vincent Libis and Guillaume Vandenesch, the company’s mission is to generate high-quality molecular data that could redefine how drugs are developed. By utilizing proprietary technology to decode these genomes, Generare is crafting a library of novel compounds characterized by their structure, biological activity, and potential therapeutic benefits.

A Game-Changing Investment

The €20 million funding round was co-led by prominent venture capital firms Alven and Daphni, with strong support from existing investors such as Galion.exe, Teampact Ventures, and VIVES Partners. This financial boost will enable Generare to scale its operations significantly, including plans to grow its team of experts and increase its molecular production capacity tenfold by 2027.

"Drug discovery has a data problem," explains Guillaume Vandenesch, CEO and co-founder of Generare. "The bottleneck is not the algorithms but the absence of genuinely novel, high-quality molecular data. Our platform is addressing this by building the largest proprietary dataset of cryptic small molecules—molecules shaped by 3 billion years of evolution."

Bridging AI and Drug Discovery

Generare’s platform is not just about data collection; it’s about creating a bridge between artificial intelligence and drug discovery. While AI can expedite the development of new medicines, it requires fresh data to explore new chemical spaces. Generare’s evolving dataset, enriched with unique, evolution-derived molecules, offers a valuable resource for AI models, enhancing their ability to generate innovative drug candidates.

"Nature has been the number one source of innovative drug action modes," says Dr. Vincent Libis, CSO and co-founder. "We’re building the infrastructure to change that with the largest commercial library of evolution-derived molecules."

The Broader Implications

For startups, founders, and investors in the biotech space, Generare's success underscores the growing importance of innovative data-driven approaches in drug discovery. As AI and machine learning become integral to pharmaceutical research, the demand for novel data sources like Generare’s will likely surge. This positions the company not just as a data provider but as a crucial player in the future of medicine.

Maria Tahri, Bio Investor at Alven, notes, "Generare is reopening nature’s pharmacy at an industrial scale. By harnessing genomics, synthetic biology, and machine learning, the company generates proprietary datasets on unknown mechanisms of action, unlocking drug opportunities others cannot see."

Conclusion

In just three years, Generare has positioned itself as a leader in evolution-based molecular data production, identifying over 200 new molecules in 2025 alone. These discoveries are now fueling research efforts to develop new treatments for life-threatening diseases. With fresh capital and an ambitious growth strategy, Generare is poised to make a lasting impact on the drug discovery landscape.

Source: EU-Startups